Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Eliasson

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
BMJ (Clinical Research Ed.)|May 20, 2006
Ethnicity and adverse drug reactionsErik Eliasson
Lakartidningen|July 2, 2008
[Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided]Erik Eliasson
Lakartidningen|May 11, 2021
[Pharmacogenomics - a cornerstone of Precision Medicine. Genomic Medicine Sweden analyses genotypes associated with serious drug toxicity or therapeutic failure]Erik Eliasson, Mia Wadelius
Lakartidningen|July 22, 2010
["Silent" interactions are often missed. Different combinations of pharmaceuticals can result in non-drug effect]Buster Mannheimer, Erik Eliasson
Lakartidningen|March 23, 2007
[Detrusitol and memory impairment]Asa Jansson, Erik Eliasson
European Journal of Clinical Pharmacology|April 9, 2002
Significant reduction of sertraline plasma levels by carbamazepine and phenytoinMaria Pihlsgård, Erik Eliasson
Carcinogenesis|April 19, 2002
Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer riskUmit Yasar, Erik Eliasson, Marja-Liisa Dahl
Lakartidningen|March 25, 2015
[Beta lactam antibiotics and the question of dose regimen for severe infection. Prolonged infusion theoretically appealing--yet no evidence of clinical benefit]Gunilla Leander, Erik Eliasson, Håkan Hanberger, et al.
Lakartidningen|April 1, 2015
[Few drugs dominate among clinically important interactions. Swedish register study lists problem drugs]Johan Holm, Birgit Eiermann, Erik Eliasson, et al.
Gait & Posture|September 2, 2014
A method to model anticipatory postural control in driver braking eventsJonas Östh, Erik Eliasson, Riender Happee, et al.
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
BMJ (Clinical Research Ed.)|May 20, 2006
Ethnicity and adverse drug reactionsErik Eliasson
Lakartidningen|July 2, 2008
[Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided]Erik Eliasson
Lakartidningen|May 11, 2021
[Pharmacogenomics - a cornerstone of Precision Medicine. Genomic Medicine Sweden analyses genotypes associated with serious drug toxicity or therapeutic failure]Erik Eliasson, Mia Wadelius
Lakartidningen|July 22, 2010
["Silent" interactions are often missed. Different combinations of pharmaceuticals can result in non-drug effect]Buster Mannheimer, Erik Eliasson
Lakartidningen|March 23, 2007
[Detrusitol and memory impairment]Asa Jansson, Erik Eliasson
European Journal of Clinical Pharmacology|April 9, 2002
Significant reduction of sertraline plasma levels by carbamazepine and phenytoinMaria Pihlsgård, Erik Eliasson
Carcinogenesis|April 19, 2002
Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer riskUmit Yasar, Erik Eliasson, Marja-Liisa Dahl
Lakartidningen|March 25, 2015
[Beta lactam antibiotics and the question of dose regimen for severe infection. Prolonged infusion theoretically appealing--yet no evidence of clinical benefit]Gunilla Leander, Erik Eliasson, Håkan Hanberger, et al.
Lakartidningen|April 1, 2015
[Few drugs dominate among clinically important interactions. Swedish register study lists problem drugs]Johan Holm, Birgit Eiermann, Erik Eliasson, et al.
Gait & Posture|September 2, 2014
A method to model anticipatory postural control in driver braking eventsJonas Östh, Erik Eliasson, Riender Happee, et al.
Pageof 9